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Abstract 
Background: G protein–coupled receptor family C group 5 member A (GPRC5A), a retinoic acid-inducible gene, is 
a lung tumor suppressor. Previously, we showed that repression of GPRC5A expression was associated with patho-
logic differentiation grade of oral squamous cell carcinomas (OSCC) and overexpression of GPRC5A gene inhibited 
the malignant phenotype in OSCC cells, suggesting that GPRC5A also functions as a tumor suppressor in oral cancer. 
However, the molecular mechanisms underlying GPRC5A deficiency in head and neck squamous cell carcinoma 
(HNSCC) are still unclear.
Methods: In this study, we used Western blot analysis and immunohistochemical (IHC) staining to investigate the 
expression of GPRC5A in both HNSCC cell lines and clinical samples. GPRC5A stable transfectants and their parental 
HNSCC cells were characterized for their biological activities in anchorage-independent growth.
Results: IHC analysis showed that, GPRC5A expression was high in normal tissue, but gradually decreased in oral 
leukoplakia, a precancerous stage, and greatly suppressed in primary cancer. Repression of GPRC5A was correlated 
with activated STAT3, which associates with aggressive clinicopathological features in HNSCC patients. Moreover, 
overexpression of GPRC5A suppressed IL-6-induced-STAT3 activation and inhibited anchorage-independent growth 
in HNSCC cells.
Conclusions: Repressed GPRC5A associates with increased tumor grade and activated STAT3, which may be used as 
a prognostic marker for tumor progression of HNSCC.
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Background
Head and neck cancer is the sixth most frequent cancer 
worldwide and the 5-year survival rate is amongst the 
lowest of the major cancers [1]. More than 90% of head 
and neck cancer occurs in the oral cavity,and more than 
90% of all malignant epithelial tumors arising in the oral 
cavity are squamous cell carcinomas [2, 3]. The concept 
that most oral squamous cell carcinomas (OSCC) arise 
from clinical pre-malignant lesions has been widely 
accepted [4]. Oral leukoplakia is one of the most fre-
quent potentially malignant lesions, and about half of 
OSCC were associated with leukoplakia [5]. Therefore, 
understanding the molecular mechanisms of oncogenesis 
from precancerous lesions to malignant tumor progres-
sion may lead to revealing the mechanism of oncogenesis 
in head and neck squamous cell carcinoma (HNSCC), 
but also identification of novel molecular predictors for 
improvement of the prognosis.
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G-protein coupled receptor family C group 5 member 
A (GPRC5A), a retinoic acid-inducible gene, was first 
cloned in 1998. GPRC5A is preferentially expressed in 
lung tissue, suggesting it may play an important role in 
this tissue. Gprc5a gene knockout lead to develop sponta-
neous lung tumors, indicating Gprc5a function as a lung 
tumor suppressor [6]. GPRC5A gene expression was fre-
quently suppressed in lung cancer and HNSCC cells [7]. 
Previously, we showed that GPRC5A is expressed in nor-
mal oral tissue at relatively high level, whereas its expres-
sion was repressed in OSCC [8]. However, it is unknown 
whether GPRC5A expression is repressed in precancer-
ous lesions, and how repression of GPRC5A is involved 
in the early stage of oncogenesis of HNSCC.
Intriguingly, persistent activation of STAT3 has been 
linked to tumorigenesis of HNSCC [9, 10]. STAT3 sign-
aling can be triggered by cytokines and growth factors 
that regulate cell proliferation, differentiation, survival, 
invasion, inflammation and immunity [11]. Interleukin-6 
(IL-6) and related cytokines bind to specific cell surface 
receptors, induce STAT activation via tyrosine phospho-
rylation at Y705 via the janus kinase (JAK) family kinases. 
The activated STAT proteins, as homo- or heterodimer, 
are then translocated into the nucleus to regulate gene 
transcription [11, 12]. Previously, STAT3 was found to 
be persistently activated in Gprc5a−/− mouse tracheal 
epithelial cells [13]. However, it is still unknown whether 
dysregulated STAT3 activation is resulted from GPRC5A 
deficiency and whether it is involved in tumorigenesis of 
HNSCC.
In this study, we examined GPRC5A expression in nor-
mal tissue, leukoplakia and primary tumors. We found 
that repression of GPRC5A occurred at an early stage 
of tumorigenesis, and associated with tumor progres-
sion. Moreover, we found that repression of GPRC5A 
is associated with activated STAT3 in HNSCC, which 
correlates with tumor progression. Importantly, over-
expression of ectopic GPRC5A in HNSCC cells inhib-
its IL-6-induced STAT3 activation and suppresses the 
anchorage-independent tumor growth. Thus, repression 
of GPRC5A has been linked to upregulation of STAT3 




Forty oral leukoplakia samples and 86 paired HNSCC 
and adjacent normal tissues were obtained from the 
Ninth People’s Hospital (Shanghai, China). All samples 
were formalin-fixed, and paraffin-embedded from surgi-
cally resected specimens. Data were collected from clini-
cal and pathologic records after approval by the Ethics 
Committee of the Ninth People’s Hospital of Shanghai.
Reagents and antibodies
Mouse monoclonal antibody to the C-terminus of 
GPRC5A which was developed and purified in Abmart 
(Shanghai, China) and rabbit anti-GPRC5A polyclonal 
antibody were the same as described in our previous 
study [8]. Mouse anti-Actin monoclonal antibody was 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). Rabbit anti-phospho-STAT3 (Tyr705) monoclonal 
antibody, Mouse anti-STAT3 (124H6) monoclonal anti-
body and Rabbit anti-SOCS3 polyclonal antibody was 
purchased from Cell Signaling Technology (Beverley, 
MA). IL-6 was purchased from Santa Cruz Biotechnol-
ogy (Santa Cruz, CA).
Immunohistochemistry
The standard IHC method was used as previous reported 
[8]. Briefly, 3-μm sections were dewaxed in xylene and 
hydrated with graded ethanol. Then, antigen retrieval 
was carried out using 0.01 M citrate buffer (pH 6.0) pres-
sure-cooking, and endogenous peroxidase activity was 
blocked with 3% hydrogen peroxide for 10 min at room 
temperature. After that, the sections were blocked for 
1  h at room temperature with 5% normal goat serum. 
The slides were incubated with the primary antibody 
(1:150 for GPRC5A and 1:400 for p-STAT3) in a moist 
chamber for overnight at 4  °C. Upon incubation with 
the primary antibody, the specimens were washed three 
times in phosphate buffer solution (PBS) and visualized 
using 3,3′-diaminobenzidine detection kit (Dako Cyto-
mation, Denmark). Samples were then counter stained 
with hematoxylin, a blue nuclear stain. Both cytoplasmic 
staining and membrane staining of GPRC5A and nuclear 
staining of p-STAT3 were considered as positive staining. 
To quantitate the score of GPRC5A expression, the mean 
percentage of positive cells was determined in at least five 
random fields at ×400 magnification in each section. The 
intensity of the immunoreactions was scored as follows: 
1+, weak; 2+, moderate; and 3+, intense. The percentage 
of positive cells and the staining intensity then were mul-
tiplied to produce an IHC staining score [14]. P-STAT3 
staining was scored as negative, 0–4%; weak, 5–29%; 
moderate, 30–49%; and strong, ≧50%. Strong staining 
was regarded as positive [15].
Cell cultures
Human oral keratinocytes (HOK) was purchased from 
Chinese Beijing North, a Biotechnology Research Insti-
tute. HNSCC-derived cell lines HN12, HN13, HN30 was 
kindly provided by the University of Maryland School 
of Dentistry. The CAL27, SCC-15 and SCC-25 cell lines 
were purchased from the American Type Culture Collec-
tion, Manassas, VA. HOK cells were cultured in RPMI-
1640 Medium (Invitrogen) supplemented with 15% fetal 
Page 3 of 11Liu et al. Cancer Cell Int  (2017) 17:34 
bovine serum (FBS). Other cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM; Gibco) supple-
mented with 10% fetal bovine serum, 1% glutamine, and 
1% penicillin–streptomycin. All cells were maintained in 
a humidified atmosphere of 5% CO2 at 37 °C.
Plasmid construction, transfection and stable transfected 
cells
As described before, the coding sequence of GPRC5A 
was obtained from cDNA of 292G lung tumor cells and 
a Myc tag was added to the C-terminus using PCR. The 
Myc-tagged GPRC5A cDNA was then subcloned into 
pcDNA3.1(+) to generate the pcDNA3.1(+)-GPRC5A-
Myc plasmid. The myc-taged GPRC5A plasmids and 
vector control plasmids were used to establish the 
CAL27-GPRC5A and CAL27-vector cell lines with the 
same methods as in our study reported previously [8].
Western blot analysis
Different cells CAL27-vector and CAL27-GPRC5A were 
treated independently with IL-6 (10 ng/ml) or untreated 
as a control. The cells were lysed in ice-cold 2×  lysis 
buffer containing 125  mM Tris–HCl (pH 6.8), 5% w/v 
SDS, and 24.75% glycerol, and subjected to total protein 
extraction according to standard procedure. Total 30 μg 
protein per lane of each sample was loaded and sepa-
rated by 10% SDS–PAGE, and then electrophoretically 
transferred onto polyvinylidene difluoride membranes 
using a wet transfer system (Invitrogen). Membranes 
were blocked for 60  min in Tris-buffered saline (TBS, 
pH 7.5) with 0.5% Tween-20 (TBST) and 5% nonfat dry 
milk. The membranes were blocked with 5% non-fat 
milk powder in TBS for 1  h and probed with first anti-
body at 4 °C overnight. After thorough washing, the blot 
was incubated with secondary antibody and coupled to 
horseradish peroxidase-conjugated anti-rabbit (1:2000) 
or anti-mouse IgG (1:2000) for 1 h at room temperature. 
The blots were developed and the immunoreactive bands 
were scanned and analyzed using the Odyssey Infrared 
Imaging System (LI-COR Biosciences, Lincoln, NE).
Immunofluorescence
The experimental protocol was performed as described 
previously [16]. Cultured cells rinsed three times with 
PBS and fixed with 3.7% formaldehyde were permeabi-
lized with 0.1% Triton X-100. After blocking in 1% BSA 
for 1  h, cells were incubated with the primary antibody 
in a moist, 4  °C chamber overnight, washed and then 
incubated for 1 h with Alexa Fluor 488 (in the dark), or 
594 donkey anti-rabbit IgG antibody (Invitrogen, Grand 
Island, NY) at room temperature. Washed cells (PBS 
containing 0.02% Tween 20), stained by mounting onto a 
slide with aqueous mounting medium containing 0.5 mg/
ml 40–6-diamidino-2-phenylindole, were examined with 
a florescence microscope.
Statistical analysis
SPSS (Statistic Package for Social Sciences) 13.0 for Win-
dows (SPSS Inc., Chicago, IL, USA) was used to analyze 
data. Statistical analysis was performed using the Chi 
square test (for biopsies) and Student’s t test. When the 
P value was <0.05, the difference was regarded as statis-
tically significant. The survival analysis was conducted 
using the Kaplan–Meier method and log-rank test.
Results
Patient characteristics
Of forty leukoplakia patients, twenty (50%) were men and 
20 were women, with a mean age of 59  years (SD 11.6, 
range 32–80 years). Of 86 HNSCC patients, forty-seven 
were men (54.7%) and 39 were women. Thirty-three of 86 
HNSCC patients (38.4%) were classified as well-differen-
tiated, 45 (52.3%) as moderately-differentiated, and the 
remaining 8 (9.3%) as poorly-differentiated. The param-
eters of HNSCC patients in this study are presented in 
Table 1.
GPRC5A mRNA is frequently repressed in HNSCC
We used public data from Oncomine (https://www.
oncomine.org) for analysis of GPRC5A expression in dif-
ferent kinds of human organs and tissues. As previously 
reported, GPRC5A was expressed predominantly in lung 
tissues. Interestingly, GPRC5A also expressed at a relative 
high level in head and neck tissues compared to other 
organs (Fig.  1a). Moreover, analysis of GPRC5A mRNA 
expression by using the dataset (Ginos Head-Neck) from 
Oncomine showed that GPRC5A mRNA level was sig-
nificantly repressed in HNSCCs as compared to that in 
normal tissues (P  <  0.05) (Fig.  1b). Thus, expression of 
GPRC5A is frequently repressed in HNSCC.
GPRC5A expression is repressed in oral leukoplakia, as well 
as in HNSCC
To determine which stage GPRC5A repression may 
occur during oncogenesis of HNSCC, we compared the 
expression of GPRC5A by IHC staining in 86 paired 
adjacent normal tissues, 40 oral leukoplakias and 86 
HNSCCs. Representative IHC results for GPRC5A pro-
tein in normal tissue, precancerous lesion and primary 
HNSCC are shown in Fig.  1c. We found that the aver-
age IHC score of GPRC5A is high in normal tissues 
(141.22 ±  66.975), whereas it was significantly lower in 
leukoplakia (76.00  ±  67.389), and greatly repressed in 
HNSCC (34.63 ± 41.389) (Fig. 1d). Thus, in comparison 
with the expression in normal tissue, GPRC5A expres-
sion was gradually suppressed during oncogenesis of 
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HNSCC (P < 0.01). This result suggests that repression of 
GPRC5A occurs at the early stage of head and neck onco-
genesis, and associates with development of HNSCC.
For further characterization the expression of GPRC5A 
in cancer cell lines, we examined the protein levels of 
GPRC5A in one normal cell line, HOK, and six different 
head and neck squamous cell lines, HN12, HN13, CAL27, 
SCC-25, SCC-15 and HN30, by immunoblot analysis. 
We found that GPRC5A protein level was the highest in 
HOK, but significantly decreased in several HNSCC cell 
lines in immunoblot (Fig. 2a). This suggests that GPRC5A 
expression was frequently repressed in HNSCC cells. 
In addition, we examined the subcellular localization 
of GPRC5A protein in both normal and tumor cells via 
immunofluorescence staining. GPRC5A was localized in 
the plasma membrane and intracellular vesicles, and no 
cellar localization difference was found between normal 
HOK and tumor HN30 cells (Fig.  2c). Taken together, 
GPRC5A was gradually repressed from normal tissue, to 
precancerous lesion, and to HNSCC.
Repression of GPRC5A is associated with aggressive 
clinicopathological features in HNSCC patients
To further character the clinical significance of 
GPRC5A, we compared the clinical parameters with 
GPRC5A expression in 86 HNSCC patients. IHC scores 
of GPRC5A were analyzed based on the clinicopatho-
logical characteristics. We found that GPRC5A repres-
sion was significantly correlated with tumor grade in 
HNSCC tissues (P < 0.01), but was not correlated with 
Table 1 GPRC5A expression and clinicopathologic features in HNSCC
* P value <0.05 was defined as significant





 Male 47 38.12 5.56 Z = −0.213 0.831
 Female 39 30.41 4.32
Smoking history
 Yes 30 33.80 7.03 Z = −0.082 0.935
 No 56 35.07 5.77
Drinking history
 Yes 22 36.50 9.14 Z = −0.203 0.839
 No 64 33.98 5.15
Lymph node metastasis
 Yes 56 41.86 9.14 Z = −0.390 0.696
 No 30 30.75 4.78
T stage
 T1 22 20.27 3.76 χ2 = 0.522 0.470
 T2 36 28.61 5.70
 T3 13 46.38 15.18
 T4 15 59.93 14.61
TNM stage
 I 20 17.9 3.33 χ2 = 1.312 0.252
 II 24 29.0 6.26
 III 21 39.9 9.67
 IV 21 51.6 12.66
Degree of tumor differentiation
 Well 33 58.5 8.63 χ2 = 17.831 <0.001*
 Moderately 45 22.5 4.12
 Poorly 8 3.75 1.26
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other parameters such as gender, TNM stage, alco-
hol or tobacco consumption (Fig.  3a, b; Table  1). Pub-
lic data which was published by Rickman et  al. [14] 
showed that patients with lower GPRC5A expression 
exhibited worse 5-year overall survival and 5-year dis-
tant metastasis-free survival (Fig.  3c, d). Although the 
difference by Kaplan–Meier survival analysis was with-
out significance, which was probably due to the relative 
small number of cases (n = 81) used, the trend is con-
sistent with what were observed in this study, repres-
sion of GPRC5A associates with malignant phenotype 
of HNSCC. Taken together, these data indicate that 
repression of GPRC5A is correlated with tumor grade, 
and poor prognosis of HNSCC.
GPRC5A repression associated with STAT3 activation, 
which correlates with tumor progression
To further explore the potential molecular mecha-
nism underlying GPRC5A repression, we analyzed the 
genome-wide transcriptome profile of CAL27-V and 
CAL27-GPRC5A cells, which was described previously 
[8] by Agilent Whole Human Genome Microarrays. We 
found that inflammatory factors, especially the inter-
leukin families such as IL-6, were reversely correlated 
with GPRC5A expression (data not shown). Because 
Gprc5a gene deletion has been implicated to increase 
STAT3 signaling in normal mouse tracheal epithelial 
cells (MTEC) [13], we asked if this pathway contributes 
to tumorigenesis of HNSCC. We then examined the 
activated STAT3, or p-STAT3 (Y705) in our 86 clinical 
HNSCC samples. IHC staining showed that the expres-
sion of p-STAT3 was correlated with tumor grade, but 
not other parameters of HNSCC (Fig. 4a; Table 2). Inter-
estingly, the expression levels of GPRC5A and p-STAT3 
were inversely correlated, even in different area from the 
same tumor tissue (Fig. 4b, c). Thus, GPRC5A repression 
correlates with STAT3 activation, which associates with 
tumorigenesis of HNSCC.
Fig. 1 Expression pattern of GPRC5A in human normal tissues and head and neck squamous cell carcinomas. a Quantification of relative GPRC5A 
mRNA levels in many different tissues was extracted from Oncomine database. Except lung tissues, head and neck tissues shows a relative accumu-
lation high GPRC5A expression. b Expression of GPRC5A were extracted from raw data published by Ginos et al. Each circle represents an individual 
sample. Whiskers (long dashes) in each group in both two graphs represent means, and 95% confidence intervals are represented by short dashes.  
c Representative images of GPRC5A expression via IHC staining in normal tissues, oral leukoplakia and HNSCC. Photos were taken under 200× mag-
nification. d IHC scores of GPRC5A expression in normal tissues (n = 86), precancerous lesions (n = 40) and HNSCC (n = 86). Statistically significant 
differences were detected (P < 0.001)
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Overexpression of GPRC5A inhibits IL-6-induced STAT3 
activation and suppresses anchorage-independent growth 
of HNSCC cells
To determine the mechanism underlying the cross-
talk between GPRC5A and p-STAT3, we examined the 
expression of STAT3 and GPRC5A in CAL27-Vector 
and CAL27-GPRC5A cells by treatment with IL-6. The 
results showed that IL-6-induced STAT3 activation 
was inhibited in CAL27-GPRC5A stable transfectants 
(Fig.  5a). Interestingly, SOCS3, a STAT3 inhibitor, is 
upregulated in CAL27-GPRC5A transfectants, suggest-
ing that SOCS3 is involved in mediation of negative regu-
lation of GPRC5A on STAT3 signaling in HNSCC cells. 
To determine the biological effects of GPRC5A overex-
pression in HNSCC, we examined the cell proliferation 
and anchorage-independent growth of these cells. The 
results showed that although cell proliferation was not 
changed (Fig. 5b), the colony formation was significantly 
suppressed in CAL27-GPRC5A cells compared to vec-
tor control (Fig. 5c). Taken together, these results suggest 
that overexpression of GPRC5A inhibits IL-6-induced 
STAT3 activation and suppress anchorage-independent 
growth of HNSCC cells.
STAT3 activation can be triggered by various cytokines 
[e.g., interleukin 6 (IL-6)] or growth factors and then 
regulate cell proliferation, differentiation, survival, inva-
sion, inflammation, and immunity [11]. Previous study 
showed that GPRC5A deficiency leads to dysregulated 
STAT3 signaling via EGF-EGFR pathway in lung cancer 
[17]. To further determine which signaling pathway to be 
essential for GPRC5A-mediated inactivation of STAT3 
in HNSCC cells, we examined the effects of inhibitors 
of EGFR, Akt, and Erk on STAT3 activation in CAL27 
cells. The results showed that wortmannin, an inhibitor 
of PI3  K, completely blocked the activation of STAT3, 
whereas erlotinib and UO126, inhibitors of EGFR and 
Erk had no inhibitory effect on IL-6-induced STAT3 acti-
vation (Fig.  5d). This suggests that dysregulated STAT3 
activation in HNSCC is independent of EGFR pathway, 
whereas PI3 K/Akt pathway is required.
Fig. 2 GPRC5A is frequently repressed in HNSCC cell lines. a Immunoblotting analysis of GPRC5A protein in the HNSCC-derived cellular lines and 
normal cell line HOK. GPRC5A protein expression is down-regulated in the HNSCC-derived cellular lines compared with that in the HOK. b Densito-
metric GPRC5A protein data in A are normalized to GAPDH protein levels. c Immunofluorescent analysis of GPRC5A subcellular localization in HOK 
and HN30 cells. Bar 50 μm
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Discussion
In this study, we showed that GPRC5A expression was 
high in normal head and neck tissues, but it was gradu-
ally decreased in leukoplakia and greatly suppressed in 
head and neck cancer. This suggests that repression of 
GPRC5A occurs at an early stage and correlates with 
oncogenesis of HNSCC. It is noticeable that patients 
grouped with low GPRC5A had a worse 5-year overall 
survival and a worse 5-year distant metastasis-free sur-
vival than those with high GPRC5A in primary tumors. 
Thus, suppression of GPRC5A may serve as a molecular 
biomarker for the oncogenesis of HNSCC.
HNSCC is derived from epithelial origin. OSCC, which 
is the most common type of HNSCC, often developed 
in a normal–dysplasia–carcinoma sequential order. 
Most of OSCC undergoes through a premalignant stage. 
Long-term follow-up studies showed that 11–36% of oral 
epithelial dysplasia was transformed into OSCC [18]. 
Leukoplakia is the most commonly diagnosed precancer-
ous lesion in the oral cavity [19, 20]. It has been shown 
that a rate of malignant transformation from leukopla-
kia to OSCC was between 17 and 24% with a median 
follow-up more than 7  years [21–23]. Thus, dysplasia 
has been considered the gold standard for evaluating the 
risk of oral cancer development [24]. Holmstrup et  al. 
[23] stated that only non-homogeneous leukoplakias 
and lesions with a size exceeding 200 mm2 were related 
to a malignant transformation. However, other variables 
parameters examined, such as degree of epithelial dys-
plasia, site, smoking and surgical intervention, were not 
found to be statistically significant factors for malignant 
development. Although the follow-up data in our leu-
koplakia patients has not been completed, our results 
suggest that the status of GPRC5A expression could 
Fig. 3 GPRC5A repression predicts aggressive clinicopathological characteristics and poor prognosis in HNSCC patients. a Representative images 
(×100 and ×400) of GPRC5A IHC staining in HNSCC with different differentiation grades. b IHC scores of GPRC5A expression for HNSCC of well 
differentiated (Grade 1), moderately differentiated (Grade 2), and poorly differentiated (Grade 3). c Low GPRC5A expression group shows a rela-
tive worse 5-year overall survival (data from Oncomine by Rickman et al.). d Low GPRC5A expression group shows a relative worse 5-year distant 
metastasis-free survival (data from Oncomine by Rickman et al.)
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enhance the predictability and reliability in cancer risk 
assessment of oral precancerous lesions, and possibly 
to improve the success of treatment (Fig.  1c, d). Taken 
together, the results of this study support the assumption 
that repression of GPRC5A may play an important role in 
oncogenesis at premalignant stages, contributing to the 
progression of head and neck carcinogenesis.
Our study showed that GPRC5A was highly expressed 
in normal tissues, but it was down-regulated in pre-
cancerous lesion, and greatly suppressed in malignant 
tumors. The repression of GPRC5A was correlated with 
tumor grade (Fig.  3a, b). Our study is supported by the 
data from Oncomine in which suppressed GPRC5A has a 
worse 5-year overall survival and distant metastasis-free 
survival. Taken together, all of these results suggest that 
GPRC5A expression may serve as a molecular biomarker 
for diagnosis and prognosis of HNSCC. Development 
of HNSCC is associated with genetic and epigenetic 
changes that lead to dysregulation of cell growth and dif-
ferentiation [25]. The genetic alterations are also present 
in premalignant lesions, suggesting a potential role in the 
process of malignant transformation [26–28]. The results 
of this study showed that GPRC5A expression is gradu-
ally repressed in oral leukoplakia and HNSCC, suggest-
ing that repression of GPRC5A pathway is involved in the 
multi-step process of head and neck carcinogenesis.
GPRC5A, also known as RAI3 and RAIG-1, was 
originally identified as a target gene induced by all-
trans-retinoic acid (ATRA). RA is known for its role as 
differentiation inducer [29, 30] and RA exhibits tumor 
suppressive activities in lung tissue. RA acts by binding 
to retinoic acid receptor (RAR), followed by formation of 
a heterodimer with retinoid X receptor (RXR). The RAR/
RXR heterodimer then binds to retinoic acid response 
elements (RAREs) in the promoter regions of its target 
genes, thereby activating downstream gene transcription 
[31]. For example, RA stimulation induces the differen-
tiation of ES cells into mesenchymal and skeletal muscle 
cells [32, 33]. The expression pattern of GPRC5A protein 
in normal epithelium by immunohistochemical staining 
is very impressive, in which GPRC5A protein exhibits at 
a relatively high level in those differentiated areas, but at 
a relative low level in those undifferentiated area (Fig. 1c). 
This suggests that the biological effects of GPRC5A 
proteins are linked to differentiation status of oral epi-
thelium. This assumption is supported by the inverse 
correlation of GPRC5A expression and tumor grade of 
HNSCC.
An increasing number of studies have reported that 
STAT3 is constitutively activated in a variety of malig-
nancies including HNSCC, and this activation is closely 
related to the process of carcinogenesis and tumor pro-
gression. IL-6 has been identified as the major ligand that 
stimulates STAT3 activation in an autocrine/paracrine 
fashion. STAT3 signaling, triggered by cytokines, e.g. 
IL-6, and growth factors, is involved in regulation of cell 
proliferation, differentiation, survival, invasion, inflam-
mation, and immunity [11]. IL-6 is expressed in psori-
atic skin and in cancerous epithelial cells in HNSCC, 
and IL-6 can be detected in the serum, tissues, and saliva 
of HNSCC patients [34–38]. Thus, IL-6/STAT3 seems 
to be a critical pathway for oncogenesis of HNSCC. In 
this study, we showed that p-STAT3 is correlated with 
tumor grade in HNSCC. Consistently, p-STAT3 expres-
sion level was high in poorly differentiated region of 
Fig. 4 STAT3 activation, which associates with tumor progression, is 
inversely correlated with GPRC5A expression. a IHC scores of p-STAT3 
expression for HNSCC of well differentiated (Grade 1), moderately 
differentiated (Grade 2), and poorly differentiated (Grade 3). b Statistic 
analysis of IHC staining for p-STAT3 in HNSCC with high and low 
GPRC5A (*P < 0.05). c Representative images (×400) of GPRC5A and 
P-STAT3 IHC staining in HNSCCs with different differentiation grades
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HNSCC, whereas STAT1 level was high in well-differ-
entiated tumor region. It has been suggested that differ-
entiation status of HNSCC is dependent on a STAT1/
STAT3 balance [39]. In agreement with our study, all 
these data showed that differentiation is inversely cor-
related with STAT3 activation in head and neck cancer 
cells. In the previous study, activated STAT3 was found 
to be higher in Gprc5a−/− cells than in wild-type cells, 
suggesting GPRC5A is involved in negative regulation 
of p-STAT3 [13]. Moreover, repressed SOCS3 is impli-
cated to be involved in dysregulated STAT3 activation in 
Gprc5a−/− MTEC. In this study, expression of GPRC5A 
was inversely correlated with activated STAT3, both in 
HNSCC cell lines and human HNSCC samples. Because 
GPRC5A expression is linked to inhibition of STAT3 
and induction of differentiation, restoration of GPRC5A 
expression may provide a novel strategy for cancer pre-
vention of HNSCC. Recently, our group reported that 
GPRC5A functions as a negative modulator of EGFR 
signaling. And repressed GPRC5A correlates with acti-
vated EGFR and STAT3 signaling in lung cancer [17], 
which explains dysregulated STAT3 induced by aber-
rantly activated EGFR in lung cancer. In this study, we 
found that EGFR inhibitor erlotinib did not blocked the 
activation of STAT3, whereas inhibitors of PI3  K/AKT 
showed great inhibition in HNSCC cells, suggesting that 
STAT3 activation in these cells is independent of EGFR 
pathway. The discrepancy may be dependent on the cel-
lular context. Taken together, targeting STAT3 signaling 
pathway or induction of GPRC5A pathway may provide 
an effective strategy for prevention of oncogenesis in 
head and neck.
Table 2 P-STAT3 expression and clinicopathologic features in HNSCC
* P value <0.05 was defined as significant





 Male 47 53.0 8.08 Z = −1.536 0.125
 Female 39 62.0 8.81
Smoking history
 Yes 30 58.0 4.52 Z = −0.218 0.827
 No 56 57.0 3.68
Drinking history
 Yes 22 56.0 5.51 Z = −0.437 0.662
 No 64 57.0 3.35
Lymph node metastasis
 Yes 56 58.0 4.99 Z = −0.889 0.374
 No 30 56.0 3.49
T stage
 T1 22 57.0 4.28 χ2 = 3.011 0.390
 T2 36 62.0 4.47
 T3 13 54.0 8.27
 T4 15 48.0 7.85
TNM stage
 I 20 58.0 4.75 χ2 = 0.415 0.937
 II 24 58.0 6.12
 III 21 60.0 5.52
 IV 21 53.0 6.34
Degree of tumor differentiation
 Well 33 47.0 4.57 χ2 = 14.376 <0.01*
 Moderately 45 60.0 3.76
 Poorly 8 81.0 4.55
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Conclusions
In conclusion, our results demonstrate that repression 
of GPRC5A correlated with activation of STAT3 and 
contribute to the oncogenesis of HNSCC. Furthermore, 
the STAT3 inhibitor, SOCS3 is involved in mediation of 
negative regulation of GPRC5A on STAT3 signaling in 
HNSCC cells.
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